Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 7/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178050 | 0.85 | AURKA (0.57) | EGFRAURKAGSK3BKDR | |
| SCHEMBL6748457 | 0.76 | CHEK1 (0.79) | EGFRAURKA | |
| SCHEMBL6748458 | 0.75 | CHEK1 (0.60) | EGFRAURKA | |
| SCHEMBL6748446 | 0.75 | CHEK1 (0.60) | EGFRAURKA | |
| SCHEMBL6748496 | 0.74 | AURKA (0.58) | EGFRAURKAGSK3BKDR | |
| SCHEMBL757769 | 0.73 | AURKA (1.00) | AURKA | |
| SCHEMBL8292220 | 0.73 | GSK3B (1.00) | EGFRAURKAGSK3BKDR | |
| SCHEMBL759088 | 0.72 | AURKA (0.83) | EGFRAURKAGSK3B | |
| SCHEMBL759303 | 0.72 | AURKA (0.82) | EGFRAURKAGSK3BKDR | |
| SCHEMBL6748470 | 0.72 | CHEK1 (0.71) | EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | EGFR 4423/4885AURKA 2909/4885GSK3B 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.